Daniel Vilchez, MD
Interventional Cardiology · Huntington, WVNPI 1316329824
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,020 of the $11,285 with a category attached, or 62.2%. 25 manufacturers reported payments, led by Medtronic at 31.6% of the total. Reporting peaked in 2022 at $4,016 and has fallen 71.9% since, to $1,127 in 2025.
Across 242 payments — averaging $46.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Abbott$1K
- Edwards Lifesciences$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$922
- Boston Scientific$870
- Terumo Medical Corporation$705
- plus $3K from 19 others
What the payments were for
- Travel & lodging$4,26538%
- Food & beverage$7,02062%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 45 | $3,572 |
| Abbott | 7 | $1,349 |
| Edwards Lifesciences | 13 | $1,348 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 89 | $922 |
| Boston Scientific | 17 | $870 |
| Terumo Medical Corporation | 8 | $705 |
| Shockwave Medical, Inc | 6 | $490 |
| Johnson & Johnson(2 entities) | 5 | $376 |
| Penumbra, Inc. | 4 | $339 |
| E.r. Squibb & Sons, L.L.C. | 20 | $293 |
| ZOLL Circulation Inc | 2 | $293 |
| Cvrx, Inc. | 6 | $185 |
| Bayer | 1 | $125 |
| Cardiovascular Systems Inc. | 1 | $120 |
| Lilly USA, LLC | 2 | $54 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Novo Nordisk | 2 | $32 |
| Boehringer Ingelheim | 2 | $32 |
| Kestra Medical Technology Services, Inc. | 2 | $29 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Insulet Corporation | 1 | $21 |
| Chiesi USA, Inc. | 1 | $18 |
| Shield Therapeutics Inc | 1 | $17 |
| Novartis | 2 | $16 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Resolute$1,734
- Diamondback Peripheral$1,162
- IN.PACT Admiral$659
- METACROSS OTW$375
- Indigo System$312
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$311
- TherOx DS2 Console$293
- Catheter$293
- Downstream Cartridge$293
- GlideWire$284
- XARELTO$275
- GENERAL VASCULAR ACCESS$186
- GLIDESHEATH SLENDER$143
- PRESSUREWIRE$129
- Adempas$125
- GENERAL ANGIOPLASTY$121
- Diamondback Coronary$120
- Barostim Neo System$119
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$114
- AVVIGO Guidance System$113
How this compares
$11,285 in reported general payments places this provider in the 65th percentile of 46 interventional cardiology providers in West Virginia.
See all interventional cardiology providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 70 | $78,102 |
| EntrestoSacubitril/Valsartan | 74 | $74,469 |
| FarxigaDapagliflozin Propanediol | 43 | $51,941 |
| XareltoRivaroxaban | 48 | $49,939 |
| Repatha SureclickEvolocumab | 34 | $25,633 |
| BrilintaTicagrelor | 18 | $18,597 |
| Metoprolol Succinate | 321 | $4,282 |
| Ranolazine ErRanolazine | 53 | $4,104 |
| Rosuvastatin Calcium | 243 | $3,374 |
| ClopidogrelClopidogrel Bisulfate | 244 | $2,709 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 247 | $2,685 |
| Flecainide Acetate | 22 | $1,670 |
| Atorvastatin Calcium | 173 | $1,537 |
| Nitroglycerin | 55 | $1,322 |
| Losartan Potassium | 137 | $1,186 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $12 | $78,10270 claims |
| NovartisEntresto | $16 | $74,46974 claims |
| Johnson & JohnsonXarelto | $376 | $49,93948 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 46 interventional cardiology providers in West Virginia.
Other interventional cardiology in Huntington
- Daniel SnavelyHuntington$120K
- Mehrette MaruHuntington$16K
- Gudjon KarlssonHuntington$6K
- Melissa LesterHuntington$4K
- David FranckeHuntington$2K
- Kanaan MansoorHuntington$589
- Frank RivasHuntington$83
- Mark BatesCharleston$288K
- Elie GharibSouth Charleston$240K
- Wissam GharibMorgantown$179K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.